- Home
- NPWR vs ORIC Comparison
NPWR vs ORIC Comparison
Compare NPWR & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPWR
- ORIC
- Stock Information
- Founded
- NPWR 2010
- ORIC 2014
- Country
- NPWR United States
- ORIC United States
- Employees
- NPWR N/A
- ORIC N/A
- Industry
- NPWR Industrial Machinery/Components
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- NPWR Energy
- ORIC Health Care
- Exchange
- NPWR Nasdaq
- ORIC Nasdaq
- Market Cap
- NPWR 699.8M
- ORIC 633.7M
- IPO Year
- NPWR N/A
- ORIC 2020
- Fundamental
- Price
- NPWR $9.31
- ORIC $9.58
- Analyst Decision
- NPWR Hold
- ORIC Strong Buy
- Analyst Count
- NPWR 2
- ORIC 9
- Target Price
- NPWR $9.50
- ORIC $18.75
- AVG Volume (30 Days)
- NPWR 635.3K
- ORIC 597.6K
- Earning Date
- NPWR 03-10-2025
- ORIC 03-10-2025
- Dividend Yield
- NPWR N/A
- ORIC N/A
- EPS Growth
- NPWR N/A
- ORIC N/A
- EPS
- NPWR 0.11
- ORIC N/A
- Revenue
- NPWR $250,000.00
- ORIC N/A
- Revenue This Year
- NPWR N/A
- ORIC N/A
- Revenue Next Year
- NPWR $7,100.29
- ORIC N/A
- P/E Ratio
- NPWR $88.01
- ORIC N/A
- Revenue Growth
- NPWR 38.12
- ORIC N/A
- 52 Week Low
- NPWR $6.57
- ORIC $6.33
- 52 Week High
- NPWR $14.28
- ORIC $16.65
- Technical
- Relative Strength Index (RSI)
- NPWR 41.69
- ORIC 54.79
- Support Level
- NPWR $8.71
- ORIC $7.86
- Resistance Level
- NPWR $11.83
- ORIC $11.15
- Average True Range (ATR)
- NPWR 0.73
- ORIC 0.72
- MACD
- NPWR -0.13
- ORIC 0.23
- Stochastic Oscillator
- NPWR 19.07
- ORIC 52.28
About NPWR NET Power Inc.
NET Power Inc is a clean energy technology company that has developed a novel power generation system which it refers to as the "NET Power Cycle is designed to produce clean, reliable and low-cost electricity from natural gas while capturing virtually all atmospheric emissions.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.